BRIEF-Theratechnologies says 82.5 pct patients achieved primary endpoint in Phase III ibalizumab trial
May 24, 2016 at 07:24 AM EDT
* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase III ibalizumab trial
